Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fizazi, K.
Right arrow Articles by Navone, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fizazi, K.
Right arrow Articles by Navone, N. M.
Clinical Cancer Research Vol. 8, 775-781, March 2002
© 2002 American Association for Cancer Research


Regular Articles

The Association of p21(WAF-1/CIP1) with Progression to Androgen-independent Prostate Cancer1

Karim Fizazi, Luis A. Martinez, Charles R. Sikes, Dennis A. Johnston, L. Clifton Stephens, Timothy J. McDonnell, Christopher J. Logothetis, Jon Trapman, Louis L. Pisters, Nelson G. Ordoñez, Patricia Troncoso and Nora M. Navone2

Departments of Genitourinary Medical Oncology [K. F., L. A. M., C. R. S., C. J. L., N. M. N.], Biostatistics [D. A. J.], Urology [L. L. P.], Molecular Pathology [T. J. M.], and Pathology [L. C. S., N. G. O., P. T.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and Department of Pathology Erasmus University, 3000 DR Rotterdam, the Netherlands [J. T.]

The molecular events leading to progression toward androgen-independent prostate cancer (AIPC) are not fully understood. The p21(WAF-1/CIP1) (p21) gene has been identified as a key factor for the regulation of cell growth. The expression of p21 was examined by immunohistochemical studies in 105 prostate cancer samples: (a) 7 of 30 (23%) androgen-dependent tumors; and (b) 36 of 75 (48%) androgen-independent tumors stained positive for p21 (P < 0.02). No association was found between p21 expression and p53, bcl-2, and the androgen receptor protein expression in bone metastases of patients with AIPC, whereas there was a significant association with a high Ki-67 index (P < 0.05). In 4 of 43 (9%) cases, tumors displayed a p53-negative, bcl-2-negative, and p21-positive phenotype. A xenograft mouse model of prostate cancer using the androgen-responsive MDA PCa 2b prostate cancer cell line was used to study p21 expression after androgen deprivation and at relapse. Androgen deprivation reduced p21 expression to undetectable levels after 14 days. Tumor relapse, defining AIPC, was associated with increased expression of p21 to levels comparable with those found before castration. In this model, p21 expression at relapse was also correlated with a high Ki-67 index. In conclusion, p21 expression is associated with the progression to AIPC. A possible explanation involves a paracrine effect of p21 mediated by the release of mitogenic and antiapoptotic factors. Another explanation involves the regulation of p21 expression by the androgen receptor, which also suggests that p21 may have antiapoptotic function in prostate cancer.




This article has been cited by other articles:


Home page
Biol. Reprod.Home page
M. Mukai, Q. Dong, M. P. Hardy, H. Kiyokawa, R. E. Peterson, and P. S. Cooke
Altered Prostatic Epithelial Proliferation and Apoptosis, Prostatic Development, and Serum Testosterone in Mice Lacking Cyclin-Dependent Kinase Inhibitors
Biol Reprod, November 1, 2005; 73(5): 951 - 958.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. Fradet, L. Lessard, L. R. Begin, P. Karakiewicz, A.-M. M. Masson, and F. Saad
Nuclear Factor-{kappa}B Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer
Clin. Cancer Res., December 15, 2004; 10(24): 8460 - 8464.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
R. Foley, D. Hollywood, and M. Lawler
Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease
Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
F. A. Sinicrope, E. Half, J. S. Morris, P. M. Lynch, J. D. Morrow, B. Levin, E. T. Hawk, D. S. Cohen, G. D. Ayers, and L. C. Stephens
Cell Proliferation and Apoptotic Indices Predict Adenoma Regression in a Placebo-Controlled Trial of Celecoxib in Familial Adenomatous Polyposis Patients
Cancer Epidemiol. Biomarkers Prev., June 1, 2004; 13(6): 920 - 927.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. B. Roninson
Tumor Cell Senescence in Cancer Treatment
Cancer Res., June 1, 2003; 63(11): 2705 - 2715.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. A. Martinez, J. Yang, E. S. Vazquez, M. del Carmen Rodriguez-Vargas, M. Olive, J.-T. Hsieh, C. J. Logothetis, and N. M. Navone
p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells
Carcinogenesis, August 1, 2002; 23(8): 1289 - 1296.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.